CAMBRIDGE, Mass.--(BUSINESS WIRE)--Caraway Therapeutics today announced that the Company will be presenting at the Stifel CNS Days event on Tuesday, March 29, 2022, at 3:00pm Eastern Time. Caraway’s Chief Executive Officer, Martin D. Williams, will highlight recent advances in the company’s lead program targeting the lysosomal cation channel, TRPML1, for the treatment of GBA-Parkinson’s disease (GBA-PD) and other rare genetic diseases.
The Company is also participating in the 21st Annual Needham Virtual Healthcare Conference, taking place April 11-14, 2022.
“Our lead program targeting the TRPML1 ion channel aims to boost lysosomal function to enhance key lipid and a-synuclein processing pathways that are compromised in GBA-PD patients,” said Williams. “I look forward to providing updates on our approach to developing treatments for genetically defined neurodegenerative and rare diseases at the upcoming Stifel and Needham events.”
About Caraway Therapeutics
Caraway Therapeutics is a biopharmaceutical company pursuing novel approaches for the treatment of genetically defined neurodegenerative and rare diseases. The company is a leader in the cutting-edge science of activating cellular recycling processes to clear toxic materials and defective cellular components by modulating lysosomal function. Caraway is utilizing its unique product engine to develop proprietary insights into lysosomal function and small molecule ion channel modulation and advance a robust pipeline of precision therapeutic candidates with disease-modifying potential for patients. The company is backed by top-tier investors, including SV Health Investors, AbbVie Ventures, MRLV Fund, Amgen Ventures, Dementia Discovery Fund, Alexandria Venture Investments and Eisai Innovation.
Caraway is based in Cambridge, MA. For more information, please visit www.carawaytx.com.
